FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281619005> ?p ?o ?g. }

• W4281619005 endingPage "e475" @default.
• W4281619005 startingPage "e465" @default.
• W4281619005 abstract "Objectives: Bivalirudin is a direct thrombin inhibitor that is being increasingly used for anticoagulation in children after ventricular assist device (VAD) implantation. While the data on bivalirudin use in pulsatile flow VADs are growing, reports on its use in patients on continuous flow (CF) VAD as well as comparisons of associated outcomes with unfractionated heparin (UFH) remain limited. Design: Retrospective cohort study. Setting: Single tertiary-quaternary referral center. Patients: All patients less than 21 years old on CF-VAD support who received bivalirudin or UFH for anticoagulation between the years 2016 and 2020. Interventions: Not applicable. Measurements and Main Results: Clinical characteristics compared between the cohorts included time to target range of anticoagulation, markers of hemolysis, and prevalence of hemocompatibility-related adverse events such as major hemorrhagic complications, ischemic stroke, and pump thrombosis. In 42 unique patients (41 HeartWare HVAD [Medtronic, Minneapolis, MN], one HeartMate 3 LVAD [Abbott Laboratories, Abbott Park, IL]) during the study period, a total of 67 encounters of IV anticoagulation infusions (29 UFH and 38 bivalirudin) were retrospectively reviewed. In comparison with use of UFH, bivalirudin was associated with lesser odds of major bleeding complications (odds ratio [OR], 0.29; 95% CI, 0.09–0.97; p = 0.038). We failed to identify any difference in odds of major thrombotic complications (OR, 2.53; 95% CI, 0.47–13.59; p = 0.450). Eight of the patients (28%) on UFH were switched to bivalirudin due to hemorrhagic or thrombotic complications or inability to achieve therapeutic anticoagulation, while two of the patients (5%) on bivalirudin were switched to UFH due to hemorrhagic complications. Bivalirudin was used for a “washout” in eight cases with concern for pump thrombosis—six had resolution of the pump thrombosis, while two needed pump exchange. Conclusions: Use of bivalirudin for anticoagulation in patients on CF-VAD support was associated with lesser odds of hemorrhagic complications compared with use of UFH. Bivalirudin “washout” was successful in medical management of six of eight cases of possible pump thrombosis." @default.
• W4281619005 created "2022-06-13" @default.
• W4281619005 creator A5001971768 @default.
• W4281619005 creator A5006708127 @default.
• W4281619005 creator A5010901253 @default.
• W4281619005 creator A5014038902 @default.
• W4281619005 creator A5019477544 @default.
• W4281619005 creator A5020047408 @default.
• W4281619005 creator A5022450535 @default.
• W4281619005 creator A5026626953 @default.
• W4281619005 creator A5036667931 @default.
• W4281619005 creator A5062202338 @default.
• W4281619005 creator A5066438416 @default.
• W4281619005 creator A5069032641 @default.
• W4281619005 creator A5069325786 @default.
• W4281619005 creator A5081728443 @default.
• W4281619005 creator A5086780527 @default.
• W4281619005 date "2022-06-10" @default.
• W4281619005 modified "2023-09-26" @default.
• W4281619005 title "Bivalirudin or Unfractionated Heparin for Anticoagulation in Pediatric Patients on Continuous Flow Ventricular Assist Device Support: Single-Center Retrospective Cohort Study" @default.
• W4281619005 cites W2973523395 @default.
• W4281619005 cites W2993035024 @default.
• W4281619005 cites W2996045162 @default.
• W4281619005 cites W3001842711 @default.
• W4281619005 cites W3024837474 @default.
• W4281619005 cites W3037954915 @default.
• W4281619005 cites W3080229892 @default.
• W4281619005 cites W3134066699 @default.
• W4281619005 cites W3136364157 @default.
• W4281619005 doi "https://doi.org/10.1097/pcc.0000000000003003" @default.
• W4281619005 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35687091" @default.
• W4281619005 hasPublicationYear "2022" @default.
• W4281619005 type Work @default.
• W4281619005 citedByCount "1" @default.
• W4281619005 countsByYear W42816190052023 @default.
• W4281619005 crossrefType "journal-article" @default.
• W4281619005 hasAuthorship W4281619005A5001971768 @default.
• W4281619005 hasAuthorship W4281619005A5006708127 @default.
• W4281619005 hasAuthorship W4281619005A5010901253 @default.
• W4281619005 hasAuthorship W4281619005A5014038902 @default.
• W4281619005 hasAuthorship W4281619005A5019477544 @default.
• W4281619005 hasAuthorship W4281619005A5020047408 @default.
• W4281619005 hasAuthorship W4281619005A5022450535 @default.
• W4281619005 hasAuthorship W4281619005A5026626953 @default.
• W4281619005 hasAuthorship W4281619005A5036667931 @default.
• W4281619005 hasAuthorship W4281619005A5062202338 @default.
• W4281619005 hasAuthorship W4281619005A5066438416 @default.
• W4281619005 hasAuthorship W4281619005A5069032641 @default.
• W4281619005 hasAuthorship W4281619005A5069325786 @default.
• W4281619005 hasAuthorship W4281619005A5081728443 @default.
• W4281619005 hasAuthorship W4281619005A5086780527 @default.
• W4281619005 hasConcept C126322002 @default.
• W4281619005 hasConcept C141071460 @default.
• W4281619005 hasConcept C156957248 @default.
• W4281619005 hasConcept C164705383 @default.
• W4281619005 hasConcept C167135981 @default.
• W4281619005 hasConcept C2776301958 @default.
• W4281619005 hasConcept C2776710957 @default.
• W4281619005 hasConcept C2777557582 @default.
• W4281619005 hasConcept C2777565915 @default.
• W4281619005 hasConcept C2778198053 @default.
• W4281619005 hasConcept C2778205648 @default.
• W4281619005 hasConcept C2778774980 @default.
• W4281619005 hasConcept C2778810321 @default.
• W4281619005 hasConcept C2779161974 @default.
• W4281619005 hasConcept C2780073493 @default.
• W4281619005 hasConcept C2780400711 @default.
• W4281619005 hasConcept C500558357 @default.
• W4281619005 hasConcept C71924100 @default.
• W4281619005 hasConcept C72563966 @default.
• W4281619005 hasConceptScore W4281619005C126322002 @default.
• W4281619005 hasConceptScore W4281619005C141071460 @default.
• W4281619005 hasConceptScore W4281619005C156957248 @default.
• W4281619005 hasConceptScore W4281619005C164705383 @default.
• W4281619005 hasConceptScore W4281619005C167135981 @default.
• W4281619005 hasConceptScore W4281619005C2776301958 @default.
• W4281619005 hasConceptScore W4281619005C2776710957 @default.
• W4281619005 hasConceptScore W4281619005C2777557582 @default.
• W4281619005 hasConceptScore W4281619005C2777565915 @default.
• W4281619005 hasConceptScore W4281619005C2778198053 @default.
• W4281619005 hasConceptScore W4281619005C2778205648 @default.
• W4281619005 hasConceptScore W4281619005C2778774980 @default.
• W4281619005 hasConceptScore W4281619005C2778810321 @default.
• W4281619005 hasConceptScore W4281619005C2779161974 @default.
• W4281619005 hasConceptScore W4281619005C2780073493 @default.
• W4281619005 hasConceptScore W4281619005C2780400711 @default.
• W4281619005 hasConceptScore W4281619005C500558357 @default.
• W4281619005 hasConceptScore W4281619005C71924100 @default.
• W4281619005 hasConceptScore W4281619005C72563966 @default.
• W4281619005 hasIssue "10" @default.
• W4281619005 hasLocation W42816190051 @default.
• W4281619005 hasLocation W42816190052 @default.
• W4281619005 hasOpenAccess W4281619005 @default.
• W4281619005 hasPrimaryLocation W42816190051 @default.
• W4281619005 hasRelatedWork W1946073935 @default.
• W4281619005 hasRelatedWork W1971656405 @default.
• W4281619005 hasRelatedWork W1989049428 @default.
• W4281619005 hasRelatedWork W2044227119 @default.

• next